OPKO Health (OPK) to Post Earnings on Thursday

OPKO Health (NASDAQ:OPK) is expected to release its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect OPKO Health to announce earnings of ($0.08) per share and revenue of $131.2330 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $124.20 million for the quarter, compared to the consensus estimate of $130.51 million. OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The firm’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same period last year, the company posted ($0.10) EPS. On average, analysts expect OPKO Health to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

OPKO Health Trading Down 2.5%

Shares of OPKO Health stock opened at $1.18 on Thursday. The firm has a market capitalization of $891.01 million, a PE ratio of -4.37 and a beta of 1.48. The company has a current ratio of 3.61, a quick ratio of 3.17 and a debt-to-equity ratio of 0.28. The firm’s 50 day moving average is $1.36 and its 200 day moving average is $1.26. OPKO Health has a 1 year low of $0.98 and a 1 year high of $1.61.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings upgraded shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $1.55.

Hedge Funds Weigh In On OPKO Health

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of OPKO Health by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock valued at $13,940,000 after buying an additional 67,973 shares during the period. Millennium Management LLC raised its stake in OPKO Health by 39.2% during the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after buying an additional 1,798,385 shares during the period. Goldman Sachs Group Inc. raised its stake in OPKO Health by 150.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after buying an additional 3,600,378 shares during the period. AQR Capital Management LLC boosted its holdings in OPKO Health by 466.7% in the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock worth $2,671,000 after acquiring an additional 1,324,988 shares in the last quarter. Finally, HRT Financial LP bought a new position in OPKO Health in the fourth quarter worth approximately $851,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.